+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
MARKSANS

Marksans Pharma Share Price

₹296.65 +9.75 (3.4%)
91.39% Gain from 52W Low

26 Oct, 2026 3:58 PM (IST)

Marksans Pharma live price: ₹296.65. It opened at ₹287 vs previous close ₹287; intraday high/low: ₹299/₹285. The 50 & 200 DMA stand at ₹309.60/₹260.10.

Marksans Pharma Performance

  • Today's Low
  • ₹285
  • Today's High
  • ₹299
  • 52 Week Low
  • ₹155
  • 52 Week High
  • ₹351
  • Open Price₹287
  • Previous Close₹287
  • Volume1,223,518
  • 50 DMA₹309.60
  • 100 DMA₹289.70
  • 200 DMA₹260.10

Marksans Pharma Chart

Investment Returns

  • Over 1 Month -11.96%
  • Over 3 Month + 20.44%
  • Over 6 Month + 55.96%
  • Over 1 Year + 67.88%

Smart Investing Starts Here Start SIP with Marksans Pharma for Steady Growth!

Invest Now

Marksans Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 26
  • PEG Ratio
  • 0.5
  • Market Cap Cr
  • 13,443
  • P/B Ratio
  • 4.2
  • Average True Range
  • 12.3
  • EPS
  • 11.4
  • Dividend Yield
  • 0.3
  • MACD Signal
  • -7.5
  • RSI
  • 40.53
  • MFI
  • 23.68

Latest Stock News Updates

Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Intimation of schedule for Q2FY27 Earnings Conference Call

Marksans Pharma Ltd - 524404 - Board Meeting Intimation for Declaration Of Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026

Marksans Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve Unaudited Financial Results of the Company (both Standalone and Consolidated) for the quarter and half year ended September 30, 2026

Marksans Pharma Ltd - 524404 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter and half year ended September 30, 2026

Marksans Pharma Financials

Marksans Pharma Technicals

EMA & SMA

Current Price
₹296.65
+ 9.75 (3.4%)
pointer
  • Bearish Moving Average 10
  • Bullish Moving Average 6
  • 20 Day
  • ₹310.30
  • 50 Day
  • ₹309.60
  • 100 Day
  • ₹289.70
  • 200 Day
  • ₹260.10

Resistance and Support

293.52 Pivot Speed
  • R3 315.60
  • R2 307.20
  • R1 301.90
  • S1 288.20
  • S2 279.80
  • S3 274.60

Marksans Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-11-04 Quarterly Results
2026-08-12 Quarterly Results
2026-05-26 Audited Results & Final Dividend
2026-02-05 Quarterly Results
2025-11-13 Quarterly Results
Date Purpose Remarks
2026-08-20 FINAL Rs.0.90 per share(90%)Final Dividend
2025-08-01 FINAL Rs.0.80 per share(80%)Final Dividend
2024-09-17 FINAL Rs.0.60 per share(60%)Final Dividend
2023-06-07 FINAL Rs.0.50 per share(50%)Final Dividend
View Marksans Pharma Dividend History Arrow

Marksans Pharma Shareholding Pattern

43.87%
31.53%
19.06%
3.72%
1.82%

About Marksans Pharma

Marksans Pharma engaged in the business of research, manufacture, marketing and selling pharmaceutical formulations. It operates two manufacturing facilities in Goa and maintains two R&D centers; one located in Goa and the other in Navi Mumbai, Maharashtra. View More
  • NSE Symbol
  • MARKSANS
  • BSE Symbol
  • 524404
  • Managing Director(Operations)
  • Mr. Sathish Kumar
  • ISIN
  • INE750C01026

Similar Stocks to Marksans Pharma

Marksans Pharma FAQs

Marksans Pharma share price is ₹296 As on 27 October, 2026 | 07:56

The Market Cap of Marksans Pharma is ₹13443.1 Cr As on 27 October, 2026 | 07:56

The P/E ratio of Marksans Pharma is 26 As on 27 October, 2026 | 07:56

The PB ratio of Marksans Pharma is 4.2 As on 27 October, 2026 | 07:56

The 52 week High & Low of Marksans Pharma is ₹351/₹155 respectively As on 27 October, 2026 | 07:56

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23